CRO#: 660947

AVeta Medical


AVeta has developed a technology to treat vaginal atrophy, a progressive and chronic condition that affects 80% of women over the age of 51.
by Brian Ledwith
74% Funded
€ 1,200,000 Funding goal
€ 886,472 Invested
7 Days to go

Company Summary :


AVeta is Galway-based. Its medical device is the only non-pharma hormone-free, safe, affordable, targeted therapy to treat vaginal symptoms of genitourinary syndrome of menopause (GSM), aka. vaginal atrophy (VA). It consists of a disposable, single-use intravaginal tip that is connected to a controller. The AVeta solution delivers a negative pressure treatment inducing an immune response to stimulate the natural healing process. 


Key highlights:

  • 80% of women globally over 51 yrs of age are affected by VA discomfort.
  • US market alone worth $2 billion
  • AVeta’s product uniquely delivers a hormone-free, safe, affordable and targeted therapy. 
  • Company has filed for patent protection.
  • European EIC grant funding secured in 2021 
  • Early in-human trials demonstrate patient relief for 80% of trialists.
  • AVeta team has impressive mix of experience in medical device development, completing clinical trials and working with regulatory bodies like the FDA, TUV and NSAI.